All News
Gemini will undertake a corporate restructuring that will see a drastic 80% of its workforce laid off.
Positive interim data from the global Phase I trial of single-dose NTLA-2001 demonstrated a mean serum TTR reduction of 93% at the highest dose level of 1.0 mg/kg by day 28.
The National Brain Tumor Society is investing over $1 million in the DNA damage response consortium’s start. Here’s how this consortium will help researchers.
Understanding the difference between talent acquisition and recruitment is vital not only for your hiring process but for the entire organization.
The FDA declined approval for Amryt Pharma’s therapeutic oleogel-S10. The topical gel is intended to treat a group of rare skin diseases called epidermolysis bullosa.
As we closed the books on year two of the COVID-19 pandemic, the Life Sciences market set records as the strongest in history.
Biocon Biologics has acquired its partner Viatris’ biosimilars assets. The transaction is part of an effort to create a global, vertically-integrated biosimilars leader.
Acrotech is looking to launch drugs with either improved efficacy and/or safety over currently available treatments in the oncology, dermatology, neuroscience and rare disease spaces.
The FDA lifts its clinical hold on Ocugen’s COVID-19 vaccine, and Ocugen announces a clinical trial for the treatment of inherited retinal diseases.
Discover the most common departments that make up a BioPharma company, learn about the responsibilities of each department and figure out which role is the right fit for you.
On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.
Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.
Celyad announced that it is voluntarily pausing a clinical trial it’s conducting with Merck after reports of two patient deaths.
Three new studies have been released—but not yet peer-reviewed—that support the wet market theory relating to COVID-19.
The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.
That’s the advice for emerging growth life sciences companies in 2022, according to attorney Frank Rahmani, partner in the global life science and capital markets practice group at Sidley Austin LLP.
The FDA said that the shared NDA documents did not show ample proof that bardoxolone methyl effectively slows down kidney function loss in patients with Alport syndrome.
The decision was intended to resolve the matter as swiftly as possible so that those who claimed to have been harmed by the product could receive expeditious compensation.
It is unknown whether tightening economic sanctions will limit Russia’s ability to ship its vaccines to areas that do not have strong manufacturing capabilities.
With nipocalimab, Janssen is hoping to take one big swing and knock the power right out of these autoantibodies.